Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.47 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25369942 | 0.92 | LTA4H (0.50) | LTA4HNR5A1DRD4DRD2DRD3 | |
| SCHEMBL20820096 | 0.86 | NR5A1 (0.53) | LTA4HNR5A1CYP19A1ESR2CYP1A2 | |
| SCHEMBL5857320 | 0.84 | MEN1 (0.45) | LTA4HCYP19A1CYP1A2LMNACYP2C19 | |
| SCHEMBL15831460 | 0.84 | DRD2 (0.44) | DRD4DRD2DRD3DUT | |
| SCHEMBL662362 | 0.83 | PPARG (0.41) | LTA4HDUTLMNACYP3A4 | |
| SCHEMBL2474081 | 0.83 | ALDH1A1 (0.54) | DRD4DRD2DRD3DUTLMNA | |
| SCHEMBL15814847 | 0.83 | TDP1 (0.47) | LTA4HAPPDUTPTGS1PTGS2 | |
| SCHEMBL31621061 | 0.83 | APP (0.42) | APPDUTCYP3A4 | |
| SCHEMBL22382365 | 0.82 | HSD17B10 (0.38) | DUTCYP3A4CHRNB2CHRNA4 | |
| SCHEMBL14648431 | 0.81 | L3MBTL1 (0.40) | DUTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563043-B | Substituted pyridines as inhibitors of DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2022-05-31 | — | — | CN | disclosed |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3049386-B9 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | UNIVERSITÄT ZU KOLN (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3049386-B1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIV KOELN (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3468953-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2019-04-17 | — | — | EP | disclosed |
| WO-2017216727-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| WO-2017216726-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-12-21 | — | — | WO | disclosed |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | UNIVERSITÄT ZU KÖLN (DE) | 2016-08-18 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | LTA4H 2265/4885NR5A1 1/4885APP 4640/4885 |
| US-20160237023-A1 | COMPOUNDS USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES | APC, BRCA1, VHL | LTA4H 768/4885NR5A1 141/4885APP 4026/4885 |
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | LTA4H 4228/4885NR5A1 81/4885APP 4745/4885 |
| US-10793509-B2 | Compounds useful in the treatment of neoplastic diseases | APC, BRCA1, VHL | LTA4H 768/4885NR5A1 141/4885APP 4026/4885 |
| US-10975056-B2 | Substituted pyridines as inhibitors of DNMT1 | DNMT1, DNMT3A, DNMT3B | LTA4H 4747/4885NR5A1 1590/4885APP 2340/4885 |
| US-20190194166-A1 | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | DNMT1, DNMT3A, DNMT3B | LTA4H 4747/4885NR5A1 1590/4885APP 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.